Esmotym-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Esomeprazole 40 mg, designed for the effective management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and reducing acid-related discomfort. The synergistic action of these agents provides comprehensive relief from acid reflux, heartburn, and associated gastrointestinal symptoms. Esmotym-DSR is indicated for patients requiring both acid suppression and prokinetic therapy, particularly in cases where monotherapy is insufficient. The capsule should be administered as prescribed by a healthcare professional, typically before meals to optimize efficacy. Caution is advised in patients with known hypersensitivity to either component, and monitoring is recommended in those with hepatic or renal impairment. Potential side effects include headache, dry mouth, abdominal cramps, and rare extrapyramidal symptoms. Esmotym-DSR Capsule offers a balanced therapeutic approach to managing upper GI motility and acid secretion disorders.